Patient preferences for personalized (N-of-1) trials: a conjoint analysis.

OBJECTIVE Despite their promise for increasing treatment precision, Personalized Trials (i.e., N-of-1 trials) have not been widely adopted. We aimed to ascertain patient preferences for Personalized Trials. STUDY DESIGN AND SETTING We recruited 501 adults with ≥2 common chronic conditions from Harris Poll Online. We used Sawtooth Software to generate 45 plausible Personalized Trial designs comprising combinations of eight key attributes (treatment selection, treatment type, clinician involvement, blinding, time commitment, self-monitoring frequency, duration, and cost) at different levels. Conditional logistic regression was used to assess relative importance of different attributes using a random utility maximization model. RESULTS Overall, participants preferred Personalized Trials with no costs vs. $100 cost (utility difference 1.52 [standard error 0.07], P < 0.001) and with less vs. more time commitment/day (0.16 [0.07], P < 0.015) but did not hold preferences for the other six attributes. In subgroup analyses, participants ≥65 years, white, and with income ≤$50,000 were more averse to costs than their counterparts (P all <0.05). CONCLUSION To optimize dissemination, Personalized Trial designers should seek to minimize out-of-pocket costs and time burden of self-monitoring. They should also consider adaptive designs that can accommodate subgroup differences in design preferences.

[1]  Audie A Atienza,et al.  Mobile health technology evaluation: the mHealth evidence workshop. , 2013, American journal of preventive medicine.

[2]  E. Shonkoff,et al.  Child and parent perspectives on healthier side dishes and beverages in restaurant kids’ meals: results from a national survey in the United States , 2017, BMC Public Health.

[3]  Zaixing Shi,et al.  Multiple Chronic Conditions and Use of Complementary and Alternative Medicine Among US Adults: Results From the 2012 National Health Interview Survey , 2016, Preventing chronic disease.

[4]  Andrew Lloyd,et al.  Conjoint analysis applications in health--a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[5]  G. Guyatt N of 1 randomized trials: a commentary. , 2016, Journal of clinical epidemiology.

[6]  P. Cunningham Chronic burdens: the persistently high out-of-pocket health care expenses faced by many Americans with chronic conditions. , 2009, Issue brief.

[7]  Chris Del Mar,et al.  Do Individualized Medication Effectiveness Tests (N-of-1 Trials) Change Clinical Decisions About Which Drugs to Use for Osteoarthritis and Chronic Pain? , 2005, American journal of therapeutics.

[8]  Sunita Vohra,et al.  N-of-1 trials to enhance patient outcomes: identifying effective therapies and reducing harms, one patient at a time. , 2016, Journal of clinical epidemiology.

[9]  D. Makuc,et al.  Health, United States, 2010; with special feature on death and dying , 2011 .

[10]  N. Schork Personalized medicine: Time for one-person trials , 2015, Nature.

[11]  G H Guyatt,et al.  The n-of-1 randomized controlled trial: clinical usefulness. Our three-year experience. , 1990, Annals of internal medicine.

[12]  John M. Rose,et al.  Applied Choice Analysis: A Primer , 2005 .

[13]  D. Asch,et al.  Wearable devices as facilitators, not drivers, of health behavior change. , 2015, JAMA.

[14]  Derrick L. Cogburn,et al.  HCI in the so-called developing world: what's in it for everyone , 2003, INTR.

[15]  J A Sloan,et al.  The Control Preferences Scale. , 1997, The Canadian journal of nursing research = Revue canadienne de recherche en sciences infirmieres.

[16]  Eileen J. Carter,et al.  Patients and primary care providers identify opportunities for personalized (N-of-1) trials in the mobile health era. , 2017, Journal of clinical epidemiology.

[17]  N. Schork,et al.  The n-of-1 clinical trial: the ultimate strategy for individualizing medicine? , 2011, Personalized medicine.

[18]  Peter Martinsson,et al.  Design techniques for stated preference methods in health economics. , 2003, Health economics.

[19]  R. Kravitz,et al.  N-of-1 Trials in the Medical Literature: A Systematic Review , 2011, Medical care.

[20]  Robert A Hegele,et al.  N-of-1 (Single-Patient) Trials for Statin-Related Myalgia , 2014, Annals of Internal Medicine.

[21]  K. Stange,et al.  Perspectives in Primary Care: Implementing Patient-Centered Care Coordination for Individuals with Multiple Chronic Medical Conditions , 2014, The Annals of Family Medicine.

[22]  Christopher H. Schmid,et al.  Single-patient (n-of-1) trials: a pragmatic clinical decision methodology for patient-centered comparative effectiveness research. , 2013, Journal of clinical epidemiology.

[23]  D. McFadden Econometric analysis of qualitative response models , 1984 .

[24]  Katharina Stibrant Sunnerhagen,et al.  Person-Centered Care — Ready for Prime Time , 2011, European journal of cardiovascular nursing : journal of the Working Group on Cardiovascular Nursing of the European Society of Cardiology.

[25]  R. Kravitz,et al.  Marketing therapeutic precision: Potential facilitators and barriers to adoption of n-of-1 trials. , 2009, Contemporary clinical trials.

[26]  Kathryn A Phillips,et al.  Measuring what people value: a comparison of "attitude" and "preference" surveys. , 2002, Health services research.

[27]  P. Onghena N-of-1 randomized clinical trials , 2007 .

[28]  B. Orme Getting Started with Conjoint Analysis: Strategies for Product Design and Pricing Research , 2005 .

[29]  N. Duan,et al.  Use of conjoint analysis to assess HIV vaccine acceptability: feasibility of an innovation in the assessment of consumer health-care preferences , 2012, International journal of STD & AIDS.

[30]  Richard L Kravitz,et al.  What ever happened to N-of-1 trials? Insiders' perspectives and a look to the future. , 2008, The Milbank quarterly.